Not Yet Recruiting
A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
NCT06419205
- Conditions
- Autoimmune Diseases, C3 (Complement Component 3) Glomerulopathy, Complement Component 3 Deficiency, Autosomal Recessive, +16 more
- Locations
-
Not specified